1 Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. The New England journal of medicine359, 378-390, doi:10.1056/NEJMoa0708857 (2008).
2 Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The Lancet. Oncology10, 25-34, doi:10.1016/s1470-2045(08)70285-7 (2009).
3 Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet (London, England)391, 1163-1173, doi:10.1016/s0140-6736(18)30207-1 (2018).
4 Finn, R. S. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. The New England journal of medicine382, 1894-1905, doi:10.1056/NEJMoa1915745 (2020).
5 Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, doi:10.1038/s41586-021-03362-0 (2021).
6 EASL clinical practical guidelines: management of alcoholic liver disease. Journal of hepatology57, 399-420, doi:10.1016/j.jhep.2012.04.004 (2012).
7 Mittal, S. & El-Serag, H. B. Epidemiology of hepatocellular carcinoma: consider the population. Journal of clinical gastroenterology47 Suppl, S2-6, doi:10.1097/MCG.0b013e3182872f29 (2013).
8 Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology142, 1592-1609, doi:10.1053/j.gastro.2012.04.001 (2012).
9 Bruix, J. & Sherman, M. Management of hepatocellular carcinoma. Hepatology (Baltimore, Md.)42, 1208-1236, doi:10.1002/hep.20933 (2005).
10 Di Martino, M. et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. Radiology256, 806-816, doi:10.1148/radiol.10091334 (2010).
11 Sano, K. et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology261, 834-844, doi:10.1148/radiol.11101840 (2011).
12 Hiraoka, A. et al. Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid. Oncology letters1, 57-61, doi:10.3892/ol_00000010 (2010).
13 Hiraoka, A., Hiasa, Y., Onji, M. & Michitaka, K. New contrast enhanced ultrasonography agent: impact of Sonazoid on radiofrequency ablation. Journal of gastroenterology and hepatology26, 616-618, doi:10.1111/j.1440-1746.2011.06678.x (2011).
14 Forner, A., Reig, M. & Bruix, J. Hepatocellular carcinoma. Lancet (London, England)391, 1301-1314, doi:10.1016/s0140-6736(18)30010-2 (2018).
15 the. et al.The general rules for the clinical and pathological study of primary liver cancer. 6th edition, 26 (2015).
16 Pugh, R. N., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C. & Williams, R. Transection of the oesophagus for bleeding oesophageal varices. The British journal of surgery60, 646-649 (1973).
17 Johnson, P. J. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. Journal of clinical oncology : official journal of the American Society of Clinical Oncology33, 550-558, doi:10.1200/jco.2014.57.9151 (2015).
18 Hiraoka, A. et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. Journal of gastroenterology and hepatology31, 1031-1036, doi:10.1111/jgh.13250 (2016).
19 Hiraoka, A. et al. Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver cancer6, 204-215, doi:10.1159/000452846 (2017).
20 Hiraoka, A. et al. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver cancer6, 325-336, doi:10.1159/000479984 (2017).
21 Hiraoka, A. et al. Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver cancer8, 121-129, doi:10.1159/000488778 (2019).
22 Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England : 1990)45, 228-247, doi:10.1016/j.ejca.2008.10.026 (2009).
23 Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in liver disease30, 52-60, doi:10.1055/s-0030-1247132 (2010).
24 National, Cancer & Institute. https://ctep.cancer.gov/protocolDevelopment/adverse_effects.htm (Accessed January 23, 2021).
25 Kanda, Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone marrow transplantation48, 452-458, doi:10.1038/bmt.2012.244 (2013).
26 Finn, R. et al. IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). EASL liver cancer summit 2021, #O-05 (2021).
27 Bruix, J. et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. Journal of hepatology67, 999-1008, doi:10.1016/j.jhep.2017.06.026 (2017).
28 Hiraoka, A. et al. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. Oncology, 1-9, doi:10.1159/000501281 (2019).
29 Hessheimer, A. J., Forner, A., Varela, M. & Bruix, J. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. European journal of gastroenterology & hepatology22, 1239-1244, doi:10.1097/MEG.0b013e32833aa19b (2010).
30 Eguchi, Y. et al. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review. JGH Open4, 808-817, doi:10.1002/jgh3.12349 (2020).
31 Wong, R. J. et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology148, 547-555, doi:10.1053/j.gastro.2014.11.039 (2015).
32 Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md.)64, 73-84, doi:10.1002/hep.28431 (2016).
33 Tateishi, R. et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update. Journal of gastroenterology54, 367-376, doi:10.1007/s00535-018-1532-5 (2019).
34 Tateishi, R. et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. Journal of gastroenterology50, 350-360, doi:10.1007/s00535-014-0973-8 (2015).
35 Nakamura, J. et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: Report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig8, 397-410, doi:10.1111/jdi.12645 (2017).
36 Geh, D., Manas, D. M. & Reeves, H. L. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr10, 59-75, doi:10.21037/hbsn.2019.08.08 (2021).
37 Hiraoka, A. et al. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis. Hepatol Res49, 111-117, doi:10.1111/hepr.13243 (2019).
38 Hiraoka, A. et al. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. Cancer medicine8, 3719-3728, doi:10.1002/cam4.2241 (2019).
39 Hiraoka, A. et al. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. Journal of gastroenterology and hepatology, doi:10.1111/jgh.15336 (2020).